PALISADE BIO INC (PALI:NASDAQ)
$2.8 0.3 (12%)
Analysed PALISADE BIO INC (PALI:NASDAQ) News Sources
Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile
17-04-2026
yahoo.com
Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026
16-04-2026
yahoo.com
Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference
08-04-2026
yahoo.com
TSX Penny Stocks To Watch In March 2026
31-03-2026
yahoo.com
Update: Palisade Bio Shares Fall After Phase 1b Data on PALI-2108 in Fibrostenotic Crohn's Disease
31-03-2026
yahoo.com
Palisade Bio Shares Phase 1b PALI-2108 Data Showing Safety, PK and Early Crohn’s Efficacy Signals
31-03-2026
marketbeat.com
Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease
30-03-2026
yahoo.com
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges
22-03-2026
fool.com
Palisade Bio (PALI) Reports Positive Phase 1b Data for PALI-2108 in UC Patients
18-03-2026
yahoo.com
Palisade Bio Announces Participation in Two Upcoming Investor Conferences
02-03-2026
yahoo.com
What is the current price of PALISADE BIO INC (PALI:NASDAQ)?
The current price of PALISADE BIO INC (PALI:NASDAQ) is $2.8.
PALISADE BIO INC (PALI:NASDAQ) absolute price change since previous trading day?
The absolute price change of PALISADE BIO INC (PALI:NASDAQ) since the previous trading day is $0.3.
PALISADE BIO INC (PALI:NASDAQ) percentage price change since previous trading day?
The percentage price change of PALISADE BIO INC (PALI:NASDAQ) since the previous trading day is 12%.
What is the most recent average sentiment score for PALISADE BIO INC (PALI:NASDAQ)?
The most recent average sentiment score for PALISADE BIO INC (PALI:NASDAQ) is 78 out of 100.
What is the most recent average sentiment for PALISADE BIO INC (PALI:NASDAQ)?
The most recent sentiment for PALISADE BIO INC (PALI:NASDAQ) is .
SEC-8K** Filing Available For PALISADE BIO INC (PALI:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.